What the Evidence Shows About Ozempic and Gastroparesis Risk

Latest update (2026-01)

From General Health Education to Targeted Pharmacovigilance

If you or a loved one developed gastroparesis while taking Ozempic, you may be wondering what the science actually says about the link. Researchers have published studies examining delayed gastric emptying in GLP-1 users, and this page distills that evidence into clear, objective facts. The long-standing tradition of medical literature provides a critical framework for evaluating these findings, and we present that record here.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules. The mechanistic pathways linking GLP-1 receptor agonists like Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 agonists slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions, which can exacerbate or unmask gastroparesis in susceptible individuals.

Warning Gaps and Settlement Considerations

While the Ozempic prescribing information does not explicitly list gastroparesis as a warning, it does report gastrointestinal adverse reactions including dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, but the label does not specifically warn about gastroparesis as a distinct adverse event. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis or delayed gastric emptying as a potential adverse effect. This gap may be relevant for patients who develop gastroparesis after starting Ozempic, as they may not have been adequately informed of the risk. For affected patients, settlement-related considerations include the need to establish a causal link between Ozempic use and the development of gastroparesis, which requires documenting the timeline between exposure and documented harm. The onset of gastrointestinal symptoms often occurs during dose escalation, as noted in clinical trials, but gastroparesis may develop later or persist after discontinuation.

Statute of Limitations for Ozempic Claims in New Jersey

In New Jersey, the statute of limitations for product liability claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. For Ozempic-associated gastroparesis, this means patients must file a claim within two years of recognizing that their gastroparesis symptoms are linked to Ozempic use. The timeline between exposure and documented harm is critical: patients who experienced gastrointestinal adverse reactions during dose escalation and later developed confirmed gastroparesis should document the dates of Ozempic initiation, symptom onset, and medical diagnosis. The prescribing information indicates that gastrointestinal adverse reactions are most common during dose escalation, but the label does not specify a timeline for gastroparesis development (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Therefore, affected patients should seek medical records that confirm the diagnosis and establish a temporal relationship. Settlement considerations for Ozempic-related gastroparesis may involve evaluating the strength of the evidence linking the drug to the condition. While clinical trials show increased gastrointestinal adverse reactions, the specific incidence of gastroparesis is not reported in the label. Patients may need to rely on post-marketing reports or expert testimony to support causation. The risk of gastroparesis may be higher in individuals with pre-existing gastrointestinal conditions or those taking other medications that affect gastric motility.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis claim in New Jersey?

In New Jersey, the statute of limitations for product liability claims, including those related to pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. For Ozempic-associated gastroparesis, this means patients must file a claim within two years of recognizing that their gastroparesis symptoms are linked to Ozempic use.

Does the Ozempic label warn about gastroparesis?

The Ozempic prescribing information does not explicitly list gastroparesis as a warning. It reports gastrointestinal adverse reactions such as dyspepsia, gastroesophageal reflux disease, and gastritis, which overlap with gastroparesis symptoms, but there is no specific warning about gastroparesis or delayed gastric emptying as a potential adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. Ozempic Prescribing Information - DailyMed

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.